1. Cenci S, Mezghrani A, Cascio P, Bianchi G, Cerruti F, Fra A, Lelouard H, Masciarelli S, Mattioli L, Oliva L, Orsi A, Pasqualetto E, Pierre P, Ruffato E, Tagliavacca L, Sitia R. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 2006;25(5):1104-13. PMID: 16498407.
2. Bianchi G*, Oliva L*, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, Palladini G, Giuliani N, Anderson KC, Sitia R, Cenci S. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113(13):3040-9. PMID: 19164601.
3. Chauhan D, Singh A, Brahmandam M, Carrasco R, Bandi, M, Hideshima, T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. (2009). Cancer Cell. 2009;16(4):309-23. PMID: 19800576.
4. Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Bianchi G, Mani M, Bandi M, Ikeda H, Perrone G, Hu Y, Tai YT, Zheng M, Cirstea D, Santo L, Carrasco D, Munshi N, Richardson P, Anderson KC. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010;115(25):5202-13. PMID: 20382844.
5. Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA, Dispenzieri A, Therneau TM, Cerhan J, L Melton III LJ, Rajkumar SV. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood. 2010;116(12):2019-25. PMID: 20495076. Chosen for CME activity by Blood.
6. Cenci S, Oliva L, Cerruti F, Milan E, Bianchi G, Raule M, Mezghrani A, Pasqualetto E, Sitia R, Cascio P. Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol. 2012;92(5):921-31. PMID: 22685320.
7. Bianchi G, Kyle RA, Larson DR, Witzig TE, Kumar S, Dispenzieri A, Morice WG, Rajkumar SV. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27(3):680-5. PMID: 22902364.
8. Kikuchi S, Suzuki R, Ohguchi H, Yoshida Y, Lu D, Cottini F, Jakubikova J, Bianchi G, Harada T, Gorgun G, Tai YT, Richardson PG, Hideshima T, Anderson KC. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Leukemia. 2015;29(9):1918-27. PMID: 25801913.
9. Gorgun G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje NS, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman D, Richardson PG, Anderson KC. Lenalidomide Enhances Immune Checkpoint Blockade Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015;21(20):4607-18. PMID: 25979485.
10. Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2018;32(4):996-1002. PMID: 29158558.
11. Guo G, Raje N, Seifer C, Kloeber K, Isenhart R, Ha G, Yee A, O’Donnell E, Tai YT, Richardson P, Bianchi G, Laubach J, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi N, Anderson K, Knoechel B, Lohr J. Genomic discovery and clonal tracking in multiple myeloma by cell free DNA sequencing. Leukemia. 2018;32(8):1838-1841. PMID: 29749395.
12. Ehman EC, El-Sady MS, Kijewski MF, Khor YM, Jacob S, Ruberg FL, Sanchorawala V, Landau H, Yee AJ, Bianchi G, Di Carli MF, Falk RH, Hyun H, Dorbala S. Early Detection of Multiorgan Light Chain (AL) Amyloidosis by Whole Body 18F-florbetapir PET/CT. J Nucl Med. 2019;60(9):1234-1239. PMID: 30954943.
13. Ho M**, Chen T, Liu J, Dowling P, Hideshima T, Zhang L, Morelli E, Camci-Unal G, Wu X, Tai YT, Wen K, Samur M, Schlossman RL, Mazitschek R, Kavanagh EL, Lindsay S, Harada T, McCann A, Anderson KC*, O’Gorman P*, Bianchi G*. Targeting Histone Deacetylase 3 (HDAC3) in the Bone Marrow Microenvironment Inhibits Multiple Myeloma Proliferation by Modulating Exosomes and IL-6 Trans-Signaling. Leukemia. 2020;34(1):196-209. PMID: 31142847.
14. Khor YM, Cuddy S, Harms HJ, Kijewski MF, Park MA, Robertson M, Hyun H, Di Carli MF, Bianchi G, Landau H, Yee AJ, Sanchorawala V, Frederick L. Ruberg FL, Liao RL, Berk J, Falk RH, Dorbala S. Quantitative [18F]florbetapir PET/CT May Identify Lung Involvement in Patients with Systemic AL Amyloidosis. Eur J Nucl Med Mol Imaging. 2020;47(8):1998-2009. PMID: 31807884.
15. Xu Y, Fulciniti M, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R, Bianchi G, Anderson KC, Qiu L, and Munshi NC. YWHAE/14-3-3ε expression impacts the protein load contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020;136(4):468-479. PMID: 32187357.
16. Cuddy S, Bravo PE, Falk RH, El-Sady S, Kijewski MF, Park M-A, Ruberg FL, Sanchorawala V, Landau H, Yee AJ, Bianchi G, Di Carli MF, Cheng S-C, Jerosch-Herold M, Kwong RY, Liao R, Dorbala S. Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease? JACC Cardiovasc Imaging. 2020;13(6):1325-2336. PMID: 32417333.
17. Liu J, Hideshima T, Xing, Wang S, Zhou W, Samur MK, Sewastianik T, Ogiya D, An G, Gao S, Yang L, Ji T, Bianchi G, Wen K, Tai YT, Munshi N, Richardson P, Carrasco R, Cang Y and Anderson KC. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 Jun 4;7(23):eabg2697. PMID: 34088671.
18. Bianchi G, Czarnecki PG, Ho M, Roccaro AM, Sacco A, Kawano Y, Gullà A, Aktas Samur A, Chen T, Wen K, Tai YT, Moscvin M, Wu X, Camci-Unal G, Da Vià MC, Bolli N, Sewastianik T, Carrasco RD, Ghobrial IM and Anderson KC. ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discov. 2021 Jul;2(4):338-353. PMID: 34268498.
19. Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 Sep;2(5):468-483. PMID: 34568832
20. Sacco A, Federico C, Todoerti K, Ziccheddu B, Palermo V, Giacomini A, Ravelli C, Maccarinelli F, Bianchi G, Belotti A, Ribolla R, Favasuli V, Revenko AS, MacLeod RA, Willis BS, Cai H, Hauser J, Rooney C, Willis SE, Martin PL, Staniszewska AD, Ambrose H, Hanson L, Cattaneo C, Tucci A, Rossi G, Ronca R, Neri A, Mitola S, Bolli N, Presta M, Moschetta M, Ross S, Roccaro AM. Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity. Blood. 2021 Nov 4;138(18):1705-1720. PMID: 34077955.
21. Usmani SZ, Karanes C, Bensinger WI, D’Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021 Dec;35(12):3526-3533. PMID: 34050260.
22. Chen T**, Ho M, Briere J, Moscvin M, Czarnecki PG, Anderson KC, Blackwell TK, Bianchi G. Multiple Myeloma Cells Depend on the DDI2/NRF1-mediated Proteasome Stress Response for Survival. Blood Adv. 2022 Jan 25;6(2):429-440. PMID: 34649278.
23. Cuddy SAM, Jerosch-Herold M, Falk RH, Kijewski MF, Singh V, Ruberg FL, Sanchorawala V, Landau H, Maurer MS, Yee AJ, Bianchi G, Di Carli MF, Liao R, Kwong RY, Dorbala S. Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC Cardiovasc Imaging. 2022 Apr;15(4):594-603. PMID: 34922860.
24. Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, Bianchi G, Guo G, Potdar S, Seifer C, Nair MS, Kokkalis A, Kloeber JA, Shapiro S, Budano L, Mann M, Friedman R, Lipe B, Campagnaro E, O’Donnell EK, Zhang CZ, Laubach JP, Munshi NC, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG. Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia. 2022 Apr;36(4):1078-1087. PMID: 35027656.
25. O’Gorman P, Laubach JP, O’Dwyer ME, Krawczyk J, Yee AJ, Gilligan O, Cahill MR, Rosenblatt J, Quinn J, Murphy PT, DiPietro H, Perera MR, Crotty GM, Cummings K, Hayden PJ, Browne P, Savell A, O’Leary HM, O’Keeffe D, Masone K, Hennessy BJ, Guerrero Garcia T, Scott K, Saeed K, Bianchi G, Dowling P, Tierney C, Richardson PG. Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. Am J Hematol. 2022 May;97(5):562-573. PMID: 35132679.
26. Ho M, Moscvin M, Low SK, Evans B, Close S, Schlossman R, Laubach J, Paba Prada C, Glotzbecker B, Richardson PG, Bianchi G. Risk Factors for the Development of Orthostatic Hypotension During Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Leukemia and Lymphoma. 2022 Jun 14;1-10. PMID: 35699975.
27. Moscvin M, Liacos CI, Chen T, Theodorakakou F, Fotiou D, Hossain S, Rowell S, Leblebjian H, Regan E, Czarnecki P, Bagnoli F, Bolli N, Richardson P, Rennke HG, Dimopoulos MA, Kastritis E, Bianchi G. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Blood Cancer J. 2023 Feb 27;13(1):31. doi: 10.1038/s41408-023-00802-0. PMID: 36849497; PMCID: PMC9971259.
28. Moscvin M, Evans B, Bianchi G. Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions. Journal of Cancer Metastasis and Treatment. 2023; 9:17. http://dx.doi.org/10.20517/2394-4722.2022.110
1. Chauhan D, Bianchi G, Anderson KC. Targeting the UPS as therapy in multiple myeloma. BMC Biochem. 2008;9 Suppl 1:S1. PMID: 19007431.
2. Bianchi G, Ghobrial IM. Does my patient with a serum monoclonal spike have multiple myeloma? Hematol Oncol Clin North Am. 2012;26(2):383-93, ix. PMID: 22463833.
3. Bianchi G, Kumar S, Ghobrial IM, Roccaro AM. Cell Trafficking in Multiple Myeloma. Open J Hematol. 2012;3(Suppl 1). PMID: 23762527.
4. Bianchi G, Ghobrial IM. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leuk Lymphoma. 2013;54(2):229-41. PMID: 22897729.
5. Bianchi G, Sacco A, Kumar S, Rossi G, Ghobrial I, Roccaro A. Candidate genes of Waldenstrom’s macroglobulinemia: current evidence and research. Appl Clin Genet. 2013;6:33-42. PMID: 23935380.
6. Bianchi G, Anderson KC, Harris NL, Sohani AR. The heavy chain diseases: clinical and pathologic features. Oncology (Williston Park). 2014;28(1):45-53. PMID: 24683718.
7. Bianchi G, Richardson PG, Anderson KC. Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014;32(20):2125-32. PMID: 24888801.
8. Bianchi G, Anderson KC. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64(6):422-44. PMID: 25266555.
9. Bianchi G, Ghobrial IM. Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. Curr Cancer Ther Rev. 2014;10(2):70-79. PMID: 25705146.
10. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015; 125(20):3049-58. PMID: 25838343.
11. Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood. 2015;126(3):300-10. PMID: 26031917.
12. Manier S, Kawano Y, Bianchi G, Roccaro AM, Ghobrial IM. Cell autonomous and micro-environmental regulation of tumor progression in precursor states of Multiple Myeloma. Curr Opin Hematol. 2016;23(4):426-33. PMID: 27101529.
13. Ho M**, Bianchi G. Targeting Protein Synthesis and Degradation in Multiple Myeloma: A Look at What’s on the Horizon. Am J Hematol Oncol. 2017;13(3):4-14.
14. Bianchi G, Sohani AR. Heavy Chain Disease of the Small Bowel. Curr Gastroenterol Rep. 2018;20(1):3. PMID: 29372346.
15. Ho M**, McCann A*, Bianchi G*, Zhang L, Dowling P, Despina B, O’Gorman P, Anderson KC. Overcoming Multiple Myeloma Drug Resistance in the Era of Cancer “Omics”. Leuk Lymphoma. 2018;59(3):542-561. PMID: 28610537.
16. Ho M*/**, Patel A*, Hanley C, Murphy A, McSweeney T, Zhang L, McCann A, O’Gorman P, Bianchi G. Exploiting Autophagy in Multiple Myeloma. J Cancer Metastasis Treat. 2019;5:70. DOI: 10.20517/2394-4722.2019.25
17. Ho M**, Kavanagh EL, Dunne LP, Dowling P, Zhang L, Lindsay S, Bazou D, Goh CY, Hanley C, Bianchi G, Anderson KC, O’Gorman P, McCann A. Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. Cancers (Basel). 2019 Jan 9;11(1). PMID: 30634515.
18. Bianchi G, Anderson KC. Contribution of Inhibition of Protein Catabolism in Myeloma. Cancer J. 2019;25(1):11-18. PMID: 30694855.
19. Ho M**, Bianchi G, Anderson KC. Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Review of Precision Medicine and Drug Development. 5(2):67-85. PMID: 34414281.
20. Ho M**, Goh CY, Patel A, Staunton S, O’Connor R, Godeau M, Bianchi G. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clinical Lymphoma Myeloma Leukemia. 2020;20(10):e752-e768. PMID: 32651110.
21. Chen T**, Moscvin M, Bianchi G. Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment. Front Oncol. 2020;10:608815. PMID: 33251153.
22. Ho M**, Patel A, Goh CY, Moscvin M, Zhang L, Bianchi G. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia. 2020;34(12):3111-3125. PMID: 33046818.
23. Bianchi G, Kumar S. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases. Hematol Oncol Clin North Am. 2020;34(6):1009-1026. PMID: 33099420.
24. Murray D, Puig N, Kristinsson S, Usmani S, Dispenzieri A, Chng WJ, Bianchi G, Kumar S, Hajek R, Paiva B, Waage A, Rajkumar S, Durie B. Mass Spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: An International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021 Feb 1;11(2):24. PMID: 33563895.
25. Blum A, Bazou D, Ting KR, Bianchi G, Mahandran M, Mahandran H, Eustace S, Richardson PG, O’Gorman P. Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation – a case series. Br J Haematol. 2021 May;193(4):e36-e38. PMID: 33748981.
26. Bianchi G, Zhang Y, Comenzo RL. AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies. JACC CardioOncol. 2021 Oct 19;3(4):467-487. PMID: 34729520.
27. Moscvin M, Ho M, Bianchi G. Overcoming drug resistance by targeting protein homeostasis in multiple myeloma. Cancer Drug Resist 2021;4:1027-45. PMID: 35265794.